Influenza A Virus, H3N2 Subtype Infections – Pipeline Review, H1 2018

Global Markets Direct’s, ‘Influenza A Virus, H3N2 Subtype Infections – Pipeline Review, H1 2018’, provides an overview of the Influenza A Virus, H3N2 Subtype Infections pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Influenza A Virus, H3N2 Subtype Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Influenza A Virus, H3N2 Subtype Infections and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Influenza A Virus, H3N2 Subtype Infections

– The report reviews pipeline therapeutics for Influenza A Virus, H3N2 Subtype Infections by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Influenza A Virus, H3N2 Subtype Infections therapeutics and enlists all their major and minor projects

– The report assesses Influenza A Virus, H3N2 Subtype Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Influenza A Virus, H3N2 Subtype Infections

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Influenza A Virus, H3N2 Subtype Infections

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Influenza A Virus, H3N2 Subtype Infections pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

AbbVie Inc

Adimmune Corp

Aphios Corp

AusBio Ltd

BioCryst Pharmaceuticals Inc

BiondVax Pharmaceuticals Ltd

Cadila Healthcare Ltd

Celltrion Inc

Emergent BioSolutions Inc

FluGen Inc

Inovio Pharmaceuticals Inc

Jiangsu Kanion Pharmaceutical Co Ltd

Johnson & Johnson

Medicago Inc

MedImmune LLC

Mucosis BV (Inactive)

NanoViricides Inc

Novavax Inc

OPKO Health Inc

Sanofi

Sanofi Pasteur SA

Sarepta Therapeutics Inc

SK Chemicals Co Ltd

VBI Vaccines Inc

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 7

Global Markets Direct Report Coverage 7

Influenza A Virus, H3N2 Subtype Infections Overview 8

Influenza A Virus, H3N2 Subtype Infections Therapeutics Development 9

Pipeline Overview 9

Pipeline by Companies 10

Pipeline by Universities/Institutes 13

Products under Development by Companies 14

Products under Development by Universities/Institutes 18

Influenza A Virus, H3N2 Subtype Infections Therapeutics Assessment 19

Assessment by Target 19

Assessment by Mechanism of Action 21

Assessment by Route of Administration 23

Assessment by Molecule Type 25

Influenza A Virus, H3N2 Subtype Infections Companies Involved in Therapeutics Development 27

AbbVie Inc 27

Adimmune Corp 27

Aphios Corp 28

AusBio Ltd 28

BioCryst Pharmaceuticals Inc 28

BiondVax Pharmaceuticals Ltd 29

Cadila Healthcare Ltd 29

Celltrion Inc 30

Emergent BioSolutions Inc 31

FluGen Inc 31

Inovio Pharmaceuticals Inc 31

Jiangsu Kanion Pharmaceutical Co Ltd 32

Johnson & Johnson 33

Medicago Inc 33

MedImmune LLC 34

Mucosis BV (Inactive) 34

NanoViricides Inc 35

Novavax Inc 35

OPKO Health Inc 36

Sanofi 36

Sanofi Pasteur SA 37

Sarepta Therapeutics Inc 37

SK Chemicals Co Ltd 38

VBI Vaccines Inc 38

Influenza A Virus, H3N2 Subtype Infections Drug Profiles 40

APP-0205 Drug Profile 40

APP-309 Drug Profile 41

Aspidasept Drug Profile 42

AV-5075S Drug Profile 43

AV-5080 Drug Profile 44

C-05 Drug Profile 45

cetylpyridinium chloride Drug Profile 46

CTP-27 Drug Profile 47

Fluad (quadrivalent) Drug Profile 48

Gamma-Flu Drug Profile 49

influenza [strain A/H3N2] (monovalent) vaccine Drug Profile 50

influenza [strain A/H3N2] vaccine Drug Profile 51

influenza [strain A/H3N2] vaccine Drug Profile 52

influenza [strain A/H3N2] vaccine Drug Profile 53

influenza [strain A/H3N2v] vaccine Drug Profile 54

influenza [strain A/H3N2v] vaccine Drug Profile 55

influenza [strain H3N2] vaccine Drug Profile 56

influenza [strains A/H1N1 + A/H3N2 + A/H5N1] vaccine Drug Profile 57

influenza [strains A/H1N1 + A/H3N2 + B/Victoria + B/Yamagata] (quadrivalent) vaccine Drug Profile 58

influenza [strains A/H1N1 + A/H3N2 + B/Victoria + B/Yamagata] (quadrivalent) vaccine Drug Profile 60

influenza [strains A/H1N1 + A/H3N2 + B/Victoria + B/Yamagata] (quadrivalent, split virion) vaccine Drug Profile 61

influenza [strains A/H1N1 + A/H3N2 + B/Yamagata + B/Victoria] (quadrivalent) vaccine Drug Profile 62

influenza [strains A/H1N1 + A/H3N2 + B/Yamagata + B/Victoria] (quadrivalent, virus like particle) vaccine Drug Profile 63

influenza [strains A/H1N1 + A/H3N2 + B/Yamagata] (trivalent, split virion) vaccine Drug Profile 66

influenza [strains A/H1N1 + A/H3N2 + B] (quadrivalent) vaccine Drug Profile 67

influenza [strains A/H1N1 + A/H3N2 + B] (quadrivalent) vaccine Drug Profile 68

influenza [strains A/H1N1 + A/H3N2 + B] (trivalent) vaccine Drug Profile 69

influenza [strains A/H1N1 + A/H3N2 + B] (trivalent) vaccine Drug Profile 70

influenza [strains A/H1N1 + A/H3N2 + B] (trivalent, split virion) vaccine Drug Profile 71

influenza [strains A/H1N1 + A/H3N2 + B] (trivalent, split virion) vaccine Drug Profile 72

influenza [strains A/H1N1 + A/H3N2 + B] (trivalent, split virion) vaccine Drug Profile 73

influenza [strains A/H1N1 + A/H3N2 + B] vaccine Drug Profile 74

influenza [strains A/H3N2 + A/H1N1] vaccine Drug Profile 76

M-001 Drug Profile 77

MD-2009 Drug Profile 84

NBP-607 Drug Profile 85

NEO-8877 Drug Profile 87

NP-025 Drug Profile 88

NSC-61610 Drug Profile 89

NVINF-1 Drug Profile 90

NVINF-2 Drug Profile 95

Peptides for Influenza Infections Drug Profile 98

peramivir Drug Profile 99

pertussis [strain BPZE1] vaccine Drug Profile 102

pimodivir hydrochloride Drug Profile 104

PNSIA-28 Drug Profile 107

PrEP-001 Drug Profile 108

radavirsen Drug Profile 110

REDEE FLU Drug Profile 112

Small Molecules for RSV and Influenza A Infections Drug Profile 114

Small Molecules to Inhibit Neuraminidase for Influenza A Virus Infections Drug Profile 115

UV-4B Drug Profile 116

Influenza A Virus, H3N2 Subtype Infections Dormant Projects 118

Influenza A Virus, H3N2 Subtype Infections Discontinued Products 120

Influenza A Virus, H3N2 Subtype Infections Product Development Milestones 121

Featured News & Press Releases 121

Appendix 127

Methodology 127

Coverage 127

Secondary Research 127

Primary Research 127

Expert Panel Validation 127

Contact Us 127

Disclaimer 128

List of Tables

List of Tables

Number of Products under Development for Influenza A Virus, H3N2 Subtype Infections, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Products under Development by Companies, H1 2018 (Contd..2), H1 2018

Products under Development by Universities/Institutes, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Influenza A Virus, H3N2 Subtype Infections Pipeline by AbbVie Inc, H1 2018

Influenza A Virus, H3N2 Subtype Infections Pipeline by Adimmune Corp, H1 2018

Influenza A Virus, H3N2 Subtype Infections Pipeline by Aphios Corp, H1 2018

Influenza A Virus, H3N2 Subtype Infections Pipeline by AusBio Ltd, H1 2018

Influenza A Virus, H3N2 Subtype Infections Pipeline by BioCryst Pharmaceuticals Inc, H1 2018

Influenza A Virus, H3N2 Subtype Infections Pipeline by BiondVax Pharmaceuticals Ltd, H1 2018

Influenza A Virus, H3N2 Subtype Infections Pipeline by Cadila Healthcare Ltd, H1 2018

Influenza A Virus, H3N2 Subtype Infections Pipeline by Celltrion Inc, H1 2018

Influenza A Virus, H3N2 Subtype Infections Pipeline by Emergent BioSolutions Inc, H1 2018

Influenza A Virus, H3N2 Subtype Infections Pipeline by FluGen Inc, H1 2018

Influenza A Virus, H3N2 Subtype Infections Pipeline by Inovio Pharmaceuticals Inc, H1 2018

Influenza A Virus, H3N2 Subtype Infections Pipeline by Jiangsu Kanion Pharmaceutical Co Ltd, H1 2018

Influenza A Virus, H3N2 Subtype Infections Pipeline by Johnson & Johnson, H1 2018

Influenza A Virus, H3N2 Subtype Infections Pipeline by Medicago Inc, H1 2018

Influenza A Virus, H3N2 Subtype Infections Pipeline by MedImmune LLC, H1 2018

Influenza A Virus, H3N2 Subtype Infections Pipeline by Mucosis BV (Inactive), H1 2018

Influenza A Virus, H3N2 Subtype Infections Pipeline by NanoViricides Inc, H1 2018

Influenza A Virus, H3N2 Subtype Infections Pipeline by Novavax Inc, H1 2018

Influenza A Virus, H3N2 Subtype Infections Pipeline by OPKO Health Inc, H1 2018

Influenza A Virus, H3N2 Subtype Infections Pipeline by Sanofi, H1 2018

Influenza A Virus, H3N2 Subtype Infections Pipeline by Sanofi Pasteur SA, H1 2018

Influenza A Virus, H3N2 Subtype Infections Pipeline by Sarepta Therapeutics Inc, H1 2018

Influenza A Virus, H3N2 Subtype Infections Pipeline by SK Chemicals Co Ltd, H1 2018

Influenza A Virus, H3N2 Subtype Infections Pipeline by VBI Vaccines Inc, H1 2018

Influenza A Virus, H3N2 Subtype Infections Dormant Projects, H1 2018

Influenza A Virus, H3N2 Subtype Infections Dormant Projects, H1 2018 (Contd..1), H1 2018

Influenza A Virus, H3N2 Subtype Infections Discontinued Products, H1 2018

List of Figures

List of Figures

Number of Products under Development for Influenza A Virus, H3N2 Subtype Infections, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Number of Products by Top 10 Targets, H1 2018

Number of Products by Stage and Top 10 Targets, H1 2018

Number of Products by Top 10 Mechanism of Actions, H1 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Top 10 Molecule Types, H1 2018

Number of Products by Stage and Top 10 Molecule Types, H1 2018

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports